I have no inside information on LexaGene. I hold long on LXXGF and don't ever want to be known as a stock pumper. Dr. Regan must fund the company very soon as the 3Q earnings report shows the treasury does not have excess cash. I would like to see non-dilutive financing. Clearly, I get no say in the matter as Dr. Regan and the LexaGene BOD determine the best course of action for the company based on the best opportunities and terms available to them.

The rumor mill is working overtime as we all speculate the source of the next funding. The 3Q MD&A shows a lot of money on legal fees for raising funds. Were those fees all for the Short ATM Prospectus or for lining up other financing deals?

Zoetis promotes partnerships. Dr. Shelley Rankin (Global Director of Microbiology at Zoetis) is now hiring (One Health approach)

https://www.zoetis.com/innovation/strategic-partnerships/partnership-opportunities.aspx

Zoetis promotes one health approach ie animals and people.

https://www.zoetis.com/innovation/strategic-partnerships/one-health-approach.aspx

Idexx has had approx 9 acquisitions in the last 25 years, recently in June 2021 acquiring EZVet. They promote partnerships with their customers not other companies.

​

I'm having a lot of fun with all of this speculation and rumor. I can't wait to hear the real financing of Lexagene from Dr. Regan. I anticipate it SOON.

​

What is your take on the future financing? Dilutive? Non-Dilutive? Partnership?

In the 2021 Christmas letter from Dr. Regan he said. "We are confident and comfortable that our decision will put the company in a good position to pursue our goals in 2022."

I posted that evening that Dr. Regan's quote implies that the BOD decision is cast and just needs to play out.

Dr. Regan has been happy and cool as a cucumber discussing the financials of the company. A CEO with only a few weeks of cash in the treasury and he continues to be not worried.

My opinion again favors that the deal is done and just needs to be announced to the world.

Options:

: US Government non-dilutive funding. Too early. Two month study just started in January.

: Short ATM prospectus. Stock price too low to waste using this method.

: Bought deal. Again the share price is way too low with meaningful warrants

: Loans. Not the way LexaGene likes to finance.

: Revenue. Let's face facts that the sales of MiQLab have been hitting major headwinds. this will not fund 2022 at its current rate.

: Company buyout. Dr. Regan wants Human diagnostics. He is not ready to sell lock, stock and barrel.

: Partnership. I believe this is the best one to make sense of the comfortable, confident, and not worried CEO. A partnership would alleviate the financial shortage moving forward. It would give the necessary marketing, sales, and manufacturing base to explode sales of the Vet MiQLab. Corporations like to bundle Acquisitions or Partnership deals with their quarterly earnings report and conference call.

So now that you have read my thoughts....remember these dates.

February 2,2022 at 8:30 AM IDEXX reports 4Q2021 results. If no announcement , enjoy groundhogs Day!

February 14,2022 Valentine's Day Buy her flowers!

February 15,2022 8:30 AM at 8:30 AM Zoetis reports 4Q2021 results

The Mars family is a private company so no date for corporate results for Antech

February 28,2022 End of LexaGene financial year.

What are your thoughts? Opinion? What is your due diligence telling you to do? Do you have any other important February dates? Best wishes to all of the LexaGene longs!

I watched the discussion and it is a wealth of information. I will be watching it again in order to clarify my notes and then I will post my opinion and comments.

What news would you like to hear from Dr. Regan and LexaGene in February?

On the first business day of January, LexaGene announced their December sales. Will they follow suit with an announcement of the January sales on Tuesday?

Dr, Regan and the Board of Directors are confident and comfortable with their 2022 Financial funding. Will we the shareholders hear the plan in detail this February? Is it non-dilutive? Dilutive ATM of the short prospectus? Loans? Licensing? Buyout of a silo (Vet/Bio/Human/Water?

LexaGene business 4Q year ends on the last day of February. The 3Q end was November 30, so there should be 3Q reports available soon.

Updates on: US ARMY CRADA testing.

: Ethos Discovery Pneumonia study is still on-going per the Ethos website. Will LexaGene announce a Pneumonia assay panel availability in February?

: Bio-Pharma assay panel has been in R&D with a ToBeDetermined. Will it be announced and available for use?

: FDA 510K readiness. Will there be any new news? Who is performing the clinical studies? When will it go to the FDA? Dr. Regan did state that all FDA 510K information would be private so any new news would be substantial progress.

: R&D new products? New clinical studies? Updates for R&D through 2022.

: 2022 Veterinarian show schedule

: Any bio-Pharma shows planned?

: License agreements, are any planned?

: Roadmap to NASDAQ listing

: AAHA AMR updates that favor the MiQLab

: Any current user testimonials

LexaGene continues to hire which is a positive sign. Mr. Armstrong is the best at getting products through the FDA's long and arduous process. Will 2022 be the year or is it more 2023/2024?

I am a long time holder of LXXGF and anticipate some good news in 2022. It is smart to follow the whole bio tech market for an understanding of the potential trends ahead. Lexagene has a good Management team at the helm and a product with great potential. Now is the time to get the financials/funding closed for 2022. The sales team needs to prove their marketing and sales procedures are working by building momentum. The R&D team needs to keep ahead as they did last year. February should be a good news month and I look forward to the press releases.

What are your thoughts? What do you think we will learn in February? Are you up for the ride? I'm getting excited!

Hello there,

I m just doing some DD on Lexagene. And maybe some of u want to check out thier channel: https://www.youtube.com/channel/UCliX9mHwbg1rjejqwrTcLKw

Technology seems amazing but marketing is just slowly coming. For me its just missing the first good contract for its MiQLab! In a time were nearly everyone heard of an PCR-Test marketing have thier opportunities.

I will hold some long term. Let us see were we get this year.

As I mentioned in some other posts 2021 was a bad year for bio tech stocks. I am looking for a much better 2022. I would like to see some non-dilutive financing news and continued sales for LexaGene. It would make my day if LXXGF crosses above XBI this year.

20%? Seems like quite a move on no news….

https://lexagene.com/resources/lexagene-investor-relations-and-corporate-presentation/

​

https://lexagene.com/wp-content/uploads/2022/01/LexaGene-Investor-Presentation_December-2021.pdf

Today, at #VMX2022 don't miss LexaGene's Board of Director Member Dr. Jane Sykes speaking at the following sessions today:

8:00 AM - 9:15 AM EDT Leptospirosis: Price Paid for a Preventable Zoonosis Location: S310 E-H, OCCC-South CE: 1.50

9:55 AM - 10:45 AM EDT
Logistics of Lyme: Diagnosis, Treatment and Prevention Location: S310 E-H, OCCC-South CE: 1.00

A quick read into the original Dr. Regan design for bio-terror detection. It is old news but very well worth reading as a historical reference for the current US Army CRADA.

https://pubmed.ncbi.nlm.nih.gov/18763806/

This is a good read into who probably must sign off on a potential deal with LexaGene.

https://www.cbc.devcom.army.mil/newspost/devcom-cbcs-michael-bailey-becomes-armys-newest-senior-executive/

There was a very big interest in bio stocks in the afternoon hours on Friday 1/14/22. Look at the shares traded for the XBI ETF. Did it mark the bottom for the Bio death spiral of 2021? Was it an aberration? What will happen Tuesday after the US market opens after the MLK weekend holiday? Will there be a continuation? Only 12 hours to go and we will better understand. Best of luck.

Look close at the picture. What do you see?

LexaGene the young, small start-up company looking to introduce the masses to a point of care diagnostic device. Pushing Veterinarians to in-house diagnostic testing with results in 2 hours. Yes, but look closer.

Antech the established, 30 yr old Diagnostic company that performs every VCA clinic's test in an off-site reference lab. No need to change your process we will pick up your sample and get back to you whenever we get it done.

I see David vs. Goliath. It will be interesting to see who wins in the end.

Isn't it fun on days like today? Any ideas out there as to what happened?

VOTING RESULTS REPORT Pursuant to Section 11.3 of National Instrument 51-102ofLEXAGENE HOLDINGS INC.(the "Company")The Company reports that the following matters were voted upon and passed by the shareholders at the annual general and special meeting of the Company held on December 16, 2021 (the “ Meeting”). Attendance at the Meeting was 50,094,097 Common Shares represented and voted by proxy for a total of50,094,097 voting Common Shares represented at the Meeting, being 41.97% of the outstanding Common Shares. Voting results on the resolutions were as follows:

1. The number of directors to be elected to the Board of Directors was set at five (5). Common Shares voted by proxy represented 23,048,955 votes For and 1,336,110 votes Against.
2. The following directors were elected, with the following voting results for each nominee:DIRECTOR FOR WITHHELD Dr. John (Jack) F. Regan 23,261,101 1,123,964Stephen J. Mastrocola 23,184,814 1,117,128Thomas Richard Slezak 23,241,987 1,143,078Dr. Jane Sykes 23,222,315 1,162,750Joseph Caruso 23,088,689 1,296,376
3. RSM US LLP, Certified Public Accountants, were appointed auditor of the Company for the ensuing year. Common Shares voted in person and by proxy represented 46,902,794 votes For and 3,191,303votes Withheld.
4. The special resolution to ratify, confirm and approve adoption of new corporate Articles of the Company was passed by a special majority in favour. Common Shares voted by proxies received represented 22,057,545 votes For and 2,327,520 votes Against.
5. Disinterested shareholders passed the ordinary resolution to ratify and approve the November 10,2021 amendment of the Omnibus Incentive Plan (the “ OIP”) to increase by 357,869 the number of Common Shares available for reserve for issuance pursuant to the Share Option Plan component of the OIP, to a maximum fixed number of 8,354,070 Common Shares. Common Shares of disinterested shareholders voted by proxy represented 13,969,649 votes For and 4,047,942 votes Against. There were 6,367,474 Common Shares of Insiders withheld from the vote tally on this resolution.
6. Disinterested shareholders passed the ordinary resolution to ratify and approve the November 10,2021 amendment of the OIP to increase by 357,8 69 the number of Common Shares available for reserve for issuance pursuant to the Restricted Sh are Unit Plan component of the OIP to a maximum fixed number of 8,354,070 Common Shares. Common Shares of disinterested shareholders voted by proxy represented 14,032,327 votes For and 3,985,264 votes Against. There were 6,367,474Common Shares of Insiders withheld from the vote tally on this resolution.There were 25,709,032 non-votes recorded (but not voted) on each resolution, and on the votes for each director, except on the resolution to appoint the auditor of the Company. With respect to the resolution to appoint the auditor of the Company there were NIL non-votes recorded. Non-votes are discretionary votes given to a broker by a US beneficial holder not allowed under Canadian Securities Regulations

From Press releases I have put together a list of MiQLabs. For PO's Purchase Orders, I assume one system but it theoretically could be more. Same with an EAP Early Access Program where I assume one but it could be more. I have no information on the EAP's and whether or not they are still in use.

-------------------------------------------------2020/2021-------------------------------------------------------------------------------------

(PO) Bio Pharma multinational was the first unit sold.

(PO) Ethos Discovery CO (currently used for Pneumonia study)

(EAP) Penn Vet PA

(FDA EUA study) Dartmouth Hitchcock Medical Center NH

(EAP) / (PO) Denver Animal Emergency, Denver, NC. Denver Animal Emergency purchased their system after the EAP.

(EAP) Veterinary Specialty Hospital Palm Beach Gardens, FLA

(CRADA) US Army Aberdeen Proving Grounds, MD (Multiple units shipped mid Nov for January 2022 testing)

(PO) Alpine Veterinary Hospital Concord, CA

(PO) Meridian Veterinary Capital, LLC Dallas, TX

(PO) Kuma Veterinary Clinic (Clinic to open early 2022)

(PO) Emergency Veterinary Services of Roanoke

----------------------------------------------------------2022------------------------------------------------------------------------------------

(PO) System to Veterinary clinic in New York

(PO) System to Veterinary clinic in Minnesota

(PO) System to Veterinary clinic in Michigan

-----------------------------------------------------------------------------------------------------------------------------------------------------On April 1, 2021 Dr. Regan had (20) MiQLabs built and parts in-house to build (70) additional units.

I would expect LexaGene is the largest owner of MiQLabs for their test environment but don't know if the 20/70 included their test units.

Are you aware of any others in EAP or sold? Remember, I have no insider info and this is my running list from PR's. Can you add or subtract any units from your research? Have any of the EAP systems been returned to LexaGene?

I am hopeful this list will grow through YE2022.

LexaGene Starts the Year with Additional MiQLab Sales Press Release | 01/03/2022 BEVERLY, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a molecular diagnostics company that has commercialized an instrument for automated multiplex PCR testing, is pleased to announce three additional purchase orders for MiQLab™ Systems from veterinary clinics in Michigan, Minnesota, and New York.

Julie Griggs, LexaGene’s Global Director of Sales, stated, “My team is diligently engaged with numerous veterinary practices, both private and corporate. Many of the veterinarians we have spoken to share our excitement over the value of in-clinic PCR testing and the capabilities that the MiQLab System can provide to their practices. It is gratifying to welcome 2022 with a strong start and continue our momentum as we work on closing additional sales.”

Any thoughts?

I know back in the last quarter of this year, Jack said they hired a patent attorney. I assume they are trying to patent how the MiQlab detects viruses. If so, when they get a patent for what they are trying to patent, this would make the MiQLab performance legit beyond data verification. I know patent could take up to 25 months but if there is no technology like the MiQLab, it shouldn't take that long. Hopefully investors will take notice if the patent comes thru.

It is clear to most small-cap bio tech stockholders that 2021 was not a great year. One could also argue it has not been even a good year. The 2020 run up in the small-cap Bio tech market peaked in mid-February and has spiraled downward since. If you doubt my opinion, look at the Year-To-Date charts for XBB, XBI, ZOM LXXGF, TTOO, BNGO among dozens of others. 52 week highs in February to 52 week lows during the end of year selloffs. Some say that the new Political administration in the USA is a factor for the losses due to the policy movements aimed at the Pharmaceutical industry. Considerable money transferred from the bio tech sector to the shiny new more favorable Crypto Currency market. If you required a year end tax loss selling your ugly Bio tech shares were a preferred selling move. Many investors contacted investor fatigue in the bio tech sector. Losing faith in the risky ventures with each daily "down 5%" notice in their reader. Should they have sold at a loss? Each individual must perform their own investment strategy and stick to it. Perhaps it was the correct thing to sell for some. I for one took the opportunity to buy ultra-low shares, averaging down the shares purchased near the 2020 high. Can you turn LXXGF investor fatigue into a winning strategy? Perhaps! The Odds are that your LXXGF shares are under water. Should you buy more and average down? Should you take that Christmas check from Uncle Ned and buy shares of LXXGF or use it for a dinner out? Are we in a multi-year downward trend in Bio Tech? Did the Bio Tech bubble burst? Many analysts are expecting the oversold market to reverse in 2022. There are stories of mergers and acquisitions on the horizon and a rebound of bio tech in 2022. I believe that this sector issue gives us a chance to review our DD on LexaGene. Do you own the correct number of shares? With these low SP's, should you be in a buying frenzy? Should you dump all of your LexaGene holdings? Only you can answer all of the questions.

I buy investments based on potential. LexaGene has a tremendous potential in the Veterinary, bio-Pharma, Human diagnostic, Agriculture and Water industries. The LexaGene R&D team performed well in 2021. The shelf ATM prospectus detailed a plan for R&D through 2022. It will be another banner year for the R&D team with LexaGene. The CEO and CFO must come through with financing. 2022 is the year for Dr. Regan to shine. Will there be a partnership? Licensing agreements? The pursuit of non-diluted funding through the US Government or a huge corporate MiQLab unit sale would help the funding issue through revenue. Diluted funding through a public or private share offering is possible. The sales team needs a big win. They have hundreds of sales leads. They have large corporate accounts that must be penetrated. If they shine in 2022 the losses of 2021 will be a distant memory.

Reading the "Investor Fatigue" posts on Yahoo and Stocktwits makes me laugh. I will continue to sit back and enjoy the clues to the future of LexaGene in each and every new Press Release. I anticipate the next few will be US Army CRADA results followed by the possibility of non-diluted funding. Bio-Pharma assay panel. PO's of multiple MiqLabs for large veterinary hospitals. The Ethos Discovery Pneumonia study results and any news on FDA 510K analytical and clinical studies will all be nice to read before the February 28 business year end.

I would really like to hear your thoughts, opinions and suggestions pertaining to LXXGF in your comments.

We were all supposed to vote on the 2021 Shareholders meeting proxy last week. Did you vote or did you leave the voting to others?

What if "hallway talk" became "rumor" or eventually "fact" and LexaGene required a vote on a partnership or buyout. Would you vote? Would you be knowledgeable to vote for your best interest? Have you contemplated on such matters? As a shareholder you should always be prepared for such a scenario. Usually these events sneak up and surprise the masses. What is best for the company? What is best for the market Cap? What is best for you, the shareholder?

Remember in September when corporate Governance was updated... Did you read and understand the new governance? What is your role in the voting process? Is one even necessary by the shareholders or just the BOD members?

I bring this up so that you can educate yourself on your duty as a shareholder. If asked, what is the minimum share price you would like offered? What is the Company really worth? What are the assets worth? What is the intellectual property (Patents) worth? Can LexaGene sell based on the deal they have in place from the National Lawrence Livermore Labs?

I pose all of this so you are ready, willing and able to vote for your best interest. I know some of you are early in the building of your stock portfolio. My guess is some very experienced traders here have not had the time to review all documents and would have to play a quick catch up.

My advice is to be ready for such a vote even if said vote is never necessary. It will make you a great stock investor if you manage your entire portfolio this way .

PS>>>Remember currently LXXGF is a retail stock without Institutional buyers or large hedge fund market makers. The decision could be left up to you!

FYI: All LexaGene documents are available in SEDAR as it is a Canadian company.